|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
This article reviews the available data for first- and second-generation CGRP receptor antagonists, the role of CGRPs in human physiology and migraine pathophysiology and the possible mechanism of action and safety of CGRP-targeted drugs.
|
31081399 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Conclusion Our data show an unexpected 'positive' role for the endogenous pro-nociceptive migraine mediator CGRP, suggesting more careful examination of migraine prophylaxis strategy based on CGRP antagonism although it should be noted that homocysteine induced apoptosis in primary neuronal cell culture might not necessarily reproduce all the features of cell loss in the living organism.
|
27884929 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
|
30661365 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine.
|
29616494 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CGRP receptor antagonists, including olcegepant (BIBN4096BS) and telcagepant (MK-0974), can treat migraine.
|
28165287 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitor of AChE neostigmine did not change the firing <i>per se</i> but induced nociceptive activity, sensitive to d-tubocurarine, after pretreatment of meninges with the migraine mediator CGRP.
|
28496430 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The CGRP receptor antagonists telcagepant and olcegepant (BIBN4096BS) have demonstrated clinical efficacy in the treatment of migraine and there is now a need to better understand how these molecules interact with the receptor.
|
20188075 |
2010 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We have previously demonstrated that nestin/hRAMP1 mice display a light-aversive behavior that is greatly enhanced by CGRP and blocked by a CGRP receptor antagonist used to treat migraine.
|
19607849 |
2010 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Given the clear involvement of the neuropeptide CGRP in migraine and the emerging evidence for other peptides, it seems likely that neuropeptides may help "awaken" the senses and contribute to the heightened sensory state of migraine.
|
28485842 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Cortical spreading depression as a site of origin for migraine: Role of CGRP.
|
29695168 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Consequently, genes involved in CGRP synthesis or CGRP receptor genes may play a role in migraine and/or increase susceptibility.
|
23237777 |
2013 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In testing of the antimigraine drugs the capsaicin-induced skin redness with activated TRPV1 receptors in sensory neurons associated with the release of the migraine mediator CGRP has already been widely used.
|
29915934 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently.
|
30656853 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks.
|
29691490 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CGRP plays a major role in the pathophysiology of migraine.
|
31589869 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Functional blockade of CGRP, which involves either CGRP receptor antagonists or monoclonal antibodies (mAbs) to CGRP or its receptor, has recently shown clinical efficacy in migraine management.
|
29116598 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
This is relevant as the recently licensed CGRP antagonists are likely to change current treatment schemes for migraine, which strongly depends also on the comorbidities.
|
31828875 |
2020 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Amgen and Novartis are developing erenumab (AIMOVIG™, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine.
|
29968151 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Ubrogepant is a novel, oral calcitonin gene-related peptide (CGRP) receptor antagonist in development for the acute treatment of migraine.
|
31537107 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies to calcitonin gene-related peptide and its receptor (CGRP-mAbs) appear more promising for migraine because of considerably better effect and safety profiles.
|
28389966 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Therapeutic developments in migraine have come by targeting the trigeminovascular system, with the most-recent being the proof-of-principle study of calcitonin gene-related peptide (CGRP) receptor antagonists in acute migraine.
|
17141570 |
2007 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies against CGRP or the CGRP receptor have a longer duration of action and have been investigated for migraine prevention.
|
28653227 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We will further discuss the potential role of CGRP in the brainstem and its modulation for migraine therapy, given the emergence of targeted CGRP small molecule and monoclonal antibody therapies.
|
29411638 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Its central role in migraine was proven pharmacologically by the development of CGRP receptor antagonists.
|
30311143 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Ghrelin attenuated hyperalgesia induced by chronic nitroglycerin: CGRP and TRPV1 as targets for migraine management.
|
29237283 |
2018 |